Related Experiment Video

Updated: Oct 10, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Novel SERD Has PFS Edge against Breast Cancer

    Cancer Discovery
    |December 15, 2021
    PubMed

    Insights

    Elacestrant, an oral selective estrogen receptor degrader, showed a modest but significant improvement in progression-free survival for patients with advanced ER-positive/HER2-negative breast cancer. This finding is relevant for patients previously treated with endocrine therapy and CDK4/6 inhibitors.

    Area of Science:

    • Oncology
    • Endocrinology
    • Pharmacology

    Background:

    • The EMERALD trial investigated elacestrant, an oral selective estrogen receptor degrader (SERD), in patients with advanced ER-positive/HER2-negative breast cancer.
    • Patients had prior treatment with endocrine therapy and a CDK4/6 inhibitor, a common scenario in advanced disease.

    Discussion:

    • Elacestrant demonstrated a statistically significant improvement in progression-free survival (PFS) compared to standard care in this heavily pretreated population.
    • The modest magnitude of PFS benefit warrants further investigation into predictive biomarkers and optimal sequencing.

    Key Insights:

    • Elacestrant offers a new oral treatment option for patients with ER+/HER2- advanced breast cancer progressing after CDK4/6 inhibitors and endocrine therapy.
    • The study provides valuable data on the efficacy of oral SERDs in a challenging clinical setting.

    Outlook:

    • Further research may explore elacestrant in combination therapies or earlier lines of treatment.
    • Identifying patient subgroups who derive maximal benefit from elacestrant will be crucial for personalized treatment strategies.

    More Related Videos

    Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

    Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

    Published on: February 7, 2021

    5.2K
    High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts06:06

    High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

    Published on: December 20, 2024

    824

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.4K
    Tumor Progression02:07

    Tumor Progression

    Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
    Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
    6.6K